Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:AGFG1-TET3

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: AGFG1-TET3
	FusionPDB ID: 2875
	FusionGDB2.0 ID: 2875
		Hgene	Tgene
	Gene symbol	AGFG1	TET3
	Gene ID	3267	200424
	Gene name	ArfGAP with FG repeats 1	tet methylcytosine dioxygenase 3
	Synonyms	HRB\|RAB\|RIP	BEFAHRS\|hCG_40738
	Cytomap	2q36.3	2p13.1
	Type of gene	protein-coding	protein-coding
	Description	arf-GAP domain and FG repeat-containing protein 1HIV-1 Rev-binding proteinRab, Rev/Rex activation domain-binding proteinarf-GAP domain and FG repeats-containing protein 1hRIP, Rev interacting proteinnucleoporin-like protein RIPrev-interacting protei	methylcytosine dioxygenase TET3probable methylcytosine dioxygenase TET3putative methylcytosine dioxygenasetet oncogene family member 3
	Modification date	20200313	20200314
	UniProtAcc	P52594 Main function of 5'-partner protein: FUNCTION: Required for vesicle docking or fusion during acrosome biogenesis (By similarity). May play a role in RNA trafficking or localization. In case of infection by HIV-1, acts as a cofactor for viral Rev and promotes movement of Rev-responsive element-containing RNAs from the nuclear periphery to the cytoplasm. This step is essential for HIV-1 replication. {ECO:0000250, ECO:0000269\|PubMed:10613896, ECO:0000269\|PubMed:14701878, ECO:0000269\|PubMed:15749819}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000310078, ENST00000373671, ENST00000409171, ENST00000409315, ENST00000409979, ENST00000486932,	ENST00000409262,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	13 X 9 X 8=936	6 X 8 X 3=144
	# samples	15	8
	** MAII score	log2(15/936*10)=-2.64154602908752 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(8/144*10)=-0.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: AGFG1 [Title/Abstract] AND TET3 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: AGFG1 [Title/Abstract] AND TET3 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	AGFG1(228356356)-TET3(74320029), # samples:1
Anticipated loss of major functional domain due to fusion event.	AGFG1-TET3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. AGFG1-TET3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. AGFG1-TET3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. AGFG1-TET3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:228356356/chr2:74320029)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across AGFG1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across TET3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000409979	AGFG1	chr2	228356356	-	ENST00000409262	TET3	chr2	74320029	+	8880	531	45	2879	944
ENST00000310078	AGFG1	chr2	228356356	-	ENST00000409262	TET3	chr2	74320029	+	8870	521	35	2869	944
ENST00000409315	AGFG1	chr2	228356356	-	ENST00000409262	TET3	chr2	74320029	+	8663	314	23	2662	879
ENST00000373671	AGFG1	chr2	228356356	-	ENST00000409262	TET3	chr2	74320029	+	8660	311	20	2659	879
ENST00000409171	AGFG1	chr2	228356356	-	ENST00000409262	TET3	chr2	74320029	+	8660	311	20	2659	879

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000409979	ENST00000409262	AGFG1	chr2	228356356	-	TET3	chr2	74320029	+	0.000676138	0.99932384
ENST00000310078	ENST00000409262	AGFG1	chr2	228356356	-	TET3	chr2	74320029	+	0.000674303	0.99932575
ENST00000409315	ENST00000409262	AGFG1	chr2	228356356	-	TET3	chr2	74320029	+	0.000685703	0.9993143
ENST00000373671	ENST00000409262	AGFG1	chr2	228356356	-	TET3	chr2	74320029	+	0.000679555	0.9993205
ENST00000409171	ENST00000409262	AGFG1	chr2	228356356	-	TET3	chr2	74320029	+	0.000679555	0.9993205

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for AGFG1-TET3

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
AGFG1	chr2	228356356	TET3	chr2	74320029	311	97	QQEIEFLQKHGNEEEVLRKSFQDLAT
AGFG1	chr2	228356356	TET3	chr2	74320029	314	97	QQEIEFLQKHGNEEEVLRKSFQDLAT
AGFG1	chr2	228356356	TET3	chr2	74320029	521	162	QQEIEFLQKHGNEEEVLRKSFQDLAT
AGFG1	chr2	228356356	TET3	chr2	74320029	531	162	QQEIEFLQKHGNEEEVLRKSFQDLAT

Top

Potential FusionNeoAntigen Information of AGFG1-TET3 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

AGFG1-TET3_228356356_74320029.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B44:03	EEEVLRKSF	0.9982	0.9847	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:01	EEEVLRKSF	0.9964	0.8751	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B38:01	KHGNEEEVL	0.9652	0.988	8	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B38:02	KHGNEEEVL	0.9598	0.9873	8	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B45:01	NEEEVLRKS	0.9547	0.8883	11	20
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B44:03	NEEEVLRKSF	0.9992	0.9642	11	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:01	NEEEVLRKSF	0.9958	0.8525	11	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B38:01	QKHGNEEEVL	0.9669	0.94	7	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B39:05	KHGNEEEVL	0.9499	0.9608	8	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B44:10	EEEVLRKSF	0.9475	0.5693	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B44:07	EEEVLRKSF	0.9982	0.9847	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B44:26	EEEVLRKSF	0.9982	0.9847	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B44:13	EEEVLRKSF	0.9982	0.9847	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:04	EEEVLRKSF	0.9974	0.8882	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:07	EEEVLRKSF	0.9973	0.8399	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:05	EEEVLRKSF	0.9964	0.8751	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:08	EEEVLRKSF	0.9963	0.8199	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:06	EEEVLRKSF	0.9961	0.8812	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:11	EEEVLRKSF	0.9945	0.89	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:03	EEEVLRKSF	0.9915	0.8685	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B38:05	KHGNEEEVL	0.9652	0.988	8	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B41:03	EEEVLRKSF	0.5315	0.7075	12	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B39:11	KHGNEEEVL	0.51	0.9011	8	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B44:07	NEEEVLRKSF	0.9992	0.9642	11	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B44:13	NEEEVLRKSF	0.9992	0.9642	11	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B44:26	NEEEVLRKSF	0.9992	0.9642	11	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:04	NEEEVLRKSF	0.9971	0.8744	11	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:06	NEEEVLRKSF	0.9961	0.8592	11	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:05	NEEEVLRKSF	0.9958	0.8525	11	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:11	NEEEVLRKSF	0.9956	0.8892	11	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:08	NEEEVLRKSF	0.9955	0.7758	11	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B18:03	NEEEVLRKSF	0.9938	0.8476	11	21
AGFG1-TET3	chr2	228356356	chr2	74320029	521	HLA-B38:05	QKHGNEEEVL	0.9669	0.94	7	17

Top

Potential FusionNeoAntigen Information of AGFG1-TET3 in HLA II

AGFG1-TET3_228356356_74320029.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0801	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0801	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0802	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0803	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0803	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0803	EIEFLQKHGNEEEVL	2	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0804	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0804	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0805	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0806	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0807	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0808	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0808	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0809	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0810	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0811	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0811	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0812	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0813	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0814	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0814	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0814	EIEFLQKHGNEEEVL	2	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0815	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0816	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0816	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0818	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0820	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0820	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0821	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0822	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0823	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0823	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0823	EIEFLQKHGNEEEVL	2	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0824	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0826	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0826	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0827	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0827	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0827	EIEFLQKHGNEEEVL	2	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0828	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0828	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0830	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0831	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0831	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0832	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0832	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0833	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0833	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0833	EIEFLQKHGNEEEVL	2	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0835	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0835	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0835	EIEFLQKHGNEEEVL	2	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0836	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0836	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0836	EIEFLQKHGNEEEVL	2	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0837	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0837	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0838	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0838	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0838	EIEFLQKHGNEEEVL	2	17
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0839	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-0839	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1101	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1102	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1103	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1104	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1104	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1105	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1106	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1108	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1109	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1110	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1111	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1112	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1113	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1115	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1116	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1118	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1119	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1121	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1124	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1125	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1125	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1127	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1128	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1129	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1130	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1131	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1132	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1133	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1134	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1135	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1135	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1136	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1137	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1138	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1138	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1139	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1141	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1142	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1142	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1143	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1143	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1144	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1144	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1145	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1146	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1146	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1147	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1148	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1149	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1150	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1150	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1151	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1154	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1155	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1156	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1156	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1157	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1158	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1158	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1159	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1160	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1160	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1161	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1162	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1163	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1164	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1165	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1166	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1167	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1167	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1169	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1170	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1172	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1174	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1175	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1176	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1177	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1177	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1178	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1178	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1180	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1181	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1183	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1184	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1185	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1187	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1188	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1188	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1189	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1190	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1191	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1192	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1192	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1193	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1194	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1195	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1196	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1204	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1204	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1209	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1209	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1219	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1220	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1301	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1304	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1305	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1306	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1307	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1308	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1309	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-13100	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1311	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1311	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1313	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1314	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1315	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1317	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1318	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1318	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1319	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1320	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1321	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1322	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1324	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1326	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1327	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1332	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1335	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1342	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1342	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1343	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1344	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1346	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1347	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1348	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1349	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1350	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1351	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1352	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1353	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1354	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1355	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1356	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1357	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1358	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1359	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1360	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1362	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1363	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1364	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1368	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1369	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1370	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1371	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1372	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1375	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1377	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1378	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1379	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1380	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1381	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1382	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1383	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1384	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1386	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1387	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1389	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1391	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1392	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1393	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1398	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1403	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1406	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1412	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1412	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1413	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1415	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1415	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1416	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1417	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1420	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1422	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1425	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1427	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1429	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1433	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1434	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1437	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1440	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1452	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1453	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1463	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1463	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1465	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1467	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1469	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1473	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1474	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1477	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1478	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1480	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1481	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1483	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1484	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1485	QQEIEFLQKHGNEEE	0	15
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1485	QEIEFLQKHGNEEEV	1	16
AGFG1-TET3	chr2	228356356	chr2	74320029	521	DRB1-1489	QQEIEFLQKHGNEEE	0	15

Top

Fusion breakpoint peptide structures of AGFG1-TET3

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
5459	LQKHGNEEEVLRKS	AGFG1	TET3	chr2	228356356	chr2	74320029	521

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of AGFG1-TET3

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	5459	LQKHGNEEEVLRKS	-7.9962	-8.1096
HLA-B14:02	3BVN	5459	LQKHGNEEEVLRKS	-5.70842	-6.74372
HLA-B52:01	3W39	5459	LQKHGNEEEVLRKS	-6.83737	-6.95077
HLA-B52:01	3W39	5459	LQKHGNEEEVLRKS	-4.4836	-5.5189
HLA-A11:01	4UQ2	5459	LQKHGNEEEVLRKS	-10.0067	-10.1201
HLA-A11:01	4UQ2	5459	LQKHGNEEEVLRKS	-9.03915	-10.0745
HLA-A24:02	5HGA	5459	LQKHGNEEEVLRKS	-6.56204	-6.67544
HLA-A24:02	5HGA	5459	LQKHGNEEEVLRKS	-5.42271	-6.45801
HLA-B44:05	3DX8	5459	LQKHGNEEEVLRKS	-7.85648	-8.89178
HLA-B44:05	3DX8	5459	LQKHGNEEEVLRKS	-5.3978	-5.5112
HLA-A02:01	6TDR	5459	LQKHGNEEEVLRKS	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of AGFG1-TET3

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
AGFG1-TET3	chr2	228356356	chr2	74320029	11	20	NEEEVLRKS	AATGAAGAAGAAGTGCTCCGGAAGAGT
AGFG1-TET3	chr2	228356356	chr2	74320029	11	21	NEEEVLRKSF	AATGAAGAAGAAGTGCTCCGGAAGAGTTTC
AGFG1-TET3	chr2	228356356	chr2	74320029	12	21	EEEVLRKSF	GAAGAAGAAGTGCTCCGGAAGAGTTTC
AGFG1-TET3	chr2	228356356	chr2	74320029	7	17	QKHGNEEEVL	CAAAAACATGGAAATGAAGAAGAAGTGCTC
AGFG1-TET3	chr2	228356356	chr2	74320029	8	17	KHGNEEEVL	AAACATGGAAATGAAGAAGAAGTGCTC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
AGFG1-TET3	chr2	228356356	chr2	74320029	0	15	QQEIEFLQKHGNEEE	CAACAGGAAATTGAATTCTTACAAAAACATGGAAATGAAGAAGAA
AGFG1-TET3	chr2	228356356	chr2	74320029	1	16	QEIEFLQKHGNEEEV	CAGGAAATTGAATTCTTACAAAAACATGGAAATGAAGAAGAAGTG
AGFG1-TET3	chr2	228356356	chr2	74320029	2	17	EIEFLQKHGNEEEVL	GAAATTGAATTCTTACAAAAACATGGAAATGAAGAAGAAGTGCTC

Top

Information of the samples that have these potential fusion neoantigens of AGFG1-TET3

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
PRAD	AGFG1-TET3	chr2	228356356	ENST00000310078	chr2	74320029	ENST00000409262	TCGA-EJ-7315-01A

Top

Potential target of CAR-T therapy development for AGFG1-TET3

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to AGFG1-TET3

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to AGFG1-TET3

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)